U

Hadasit Bio-Holdings

Investor Israel Founded 2005
Last Update Nov 10, 2024

Hadasit Bio-Holdings News

1 article
Jun 18, 2017 · www.globes.co.il
growth-positive
Hadasit sells stem cell co Cell Cure stake
Hadasit Bio-Holdings has sold its 21% stake in Cell Cure to BioTime for $12.75 million. The deal reflects a $60 million value for Cell Cure, a stem cell company developing treatments for retinal degeneration. Hadasit believes it will post a $9 million pre-tax accounting profit following the deal. BioTime already owns 62% of Cell Cure and will have full ownership after the deal. BioTime has given Hadasit Bio-Holdings a five-year option to buy back 5% of Cell Cure. The announcement caused Hadasit Bio-Holdings share price to jump 35%.
Acquisition